Why the study?
Does bradykinin receptor antagonism alter systemic hemodynamics in patients with chronic heart failure treated with long-term ACE inhibition?
Does bradykinin receptor antagonism alter systemic hemodynamics in patients with chronic heart failure treated with long-term ACE inhibition?
Bradykinin contributes to the systemic hemodynamic effects of long-term ACE inhibition in patients with heart failure, which may explain clinical differences between ACE inhibitors and ARBs.
No takes yet. Share an insight, caveat, or question.
Bradykinin antagonism alters hemodynamics during ACE inhibition; confirms its contribution to ACEI effects and mechanistic distinction from ARBs in HF.
Cruden et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: